Therapy for advanced nonsmall cell lung cancer using icotinib hydrochloride

Abstract

Abstract:Icotinib hydrochloride is a novel oral epidermal growth factor receptortyrosine kinase inhibitor, which shows obvious inhibitory effect on nonsmall cell lung cancer (NSCLC) in vitro and in vivo. The phase Ⅲ clinical study (ICOGEN) shows that icotinib has a good efficacy for advanced retreatment NSCLC, compared with gefitinib. It is indicated for the treatment of patients with locally advanced or metastatic NSCLC previously treated with one or two chemotherapy regimens. In the clinical treatment, icotinib shows the positive effects and mild adverse reactions, especially for the patients who have the EGFR mutation.

Key words:Receptor, epidermal growth factor,Carcinoma, non-small-cell lung,Icotinib hydrochloride,Protein tyrosine kinase inhibitor

Zheng Lei, Song Zhengbo, Zhang Yiping. Therapy for advanced nonsmall cell lung cancer using icotinib hydrochloride[J]. Journal of International Oncology, 2014, 41(1): 49-52.

References

［1］张谦, 周文. 非小细胞肺癌患者的新选择——盐酸埃克替尼［J］. 药学研究, 2013, 32(2):121124. ［2］谭芬来, 王印祥, 袁晓玢, 等. EGFRTKIs治疗非小细胞肺癌进展［J］. 中国新药杂志, 2011, 20(17):15941601. ［3］ Shi Y, Zhang L, Liu X, et al. Icotinib versus gefitinib in previously treated advanced nonsmallcell lung cancer (ICOGEN): a randomised, doubleblind phase 3 noninferiority trial［J］. Lancet Oncol, 2013, 14(10):953961. ［4］谭芬来, 张力, 赵琼, 等. 国家一类新药盐酸埃克替尼的药理与临床评价［J］. 中国新药杂志, 2009, 18(18):16911694. ［5］邬楠, 王爱平, 王印祥. 表皮细胞生长因子受体酪氨酸激酶抑制剂BPI2009 的抗肿瘤作用及其机制的研究［J］. 中国临床药理学与治疗学, 2005, 10(4):456461. ［6］ Tan F, Shen X, Wang D, et al. Icotinib (BPI2009H), a novel EGFR tyrosine kinase inhibitor, displays potentefficacy in preclinical studies［J］. Lung Cancer, 2012, 76(2):177182. ［7］杨彩玲, 韩新光. 盐酸埃克替尼对人舌鳞状细胞癌Tca8113细胞增殖的影响［J］. 郑州大学学报（医学版）, 2008, 43(4):701703. ［8］关忠民, 陈笑艳, 钟大放, 等. LC/MS/MS法测定比格犬血浆中埃克替尼及其在药动学研究中的应用［J］. 中国临床药理学与治疗学, 2008, 13(10):11581162. ［9］ Guan Z, Chen X, Wang Y, et al. Metabolite identification of a new antitumor agent icotinib in rats using liquid chromatography/tandem mass spectrometry［J］. Rapid Commun Mass Spectrom, 2008, 22(14):21762184. ［10］ Liu D, Jiang J, Zhang L,et al. Metabolite characterization of a novel anticancer agent, icotinib, in humans through liquid chromatography/quadrupole timeofflight tandem mass spectrometry［J］. Rapid Commun Mass Spectrom, 2011, 25(15):21312140. ［11］ Ruan CJ, Liu DY, Jiang J, et al. Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers［J］. Eur J Clin Pharmacol, 2012, 68(12):16771680. ［12］ Zhao Q, Shentu J, Xu N, et al. Phase Ⅰ study of icotinib hydrochloride (BPI2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors［J］. Lung Cancer, 2011, 73(2):195202. ［13］ Wang HP, Zhang L, Wang YX, et al. Phase Ⅰ trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with nonsmall cell lung cancer［J］. Chin Med J (Engl), 2011, 124(13):1933. ［14］陈建华, 罗永忠, 王伟, 等. 盐酸埃克替尼治疗晚期非小细胞肺癌III期临床试验［J］. 肿瘤药学, 2011, 1(5):441443. ［15］李艳莹, 余敏, 陈芙蓉, 等. 埃克替尼一线及加量治疗表皮生长因子受体突变晚期肺腺癌患者1例［J］. 中国新药杂志, 2013, 22(11):13071310.